ACOR Stock Price, News & Analysis

Acorda Therapeutics, Inc. (ACOR) develops and commercializes therapies for neurological disorders. The company is centered on approved products for Parkinson’s disease and multiple sclerosis, together with a pulmonary drug-delivery technology used in one of its commercial products. Its business has been described through product revenue, commercialization arrangements, clinical or regulatory disclosures, material agreements, capital-structure matters, governance updates, and operating and financial results.

The company’s principal product references include INBRIJA, a levodopa inhalation powder approved for the intermittent treatment of OFF episodes in adults with Parkinson’s disease who are treated with carbidopa/levodopa. INBRIJA uses Acorda’s ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets AMPYRA, branded dalfampridine extended-release tablets, 10 mg, for the U.S. market.

Acorda’s product and rights portfolio also includes FAMPYRA, the fampridine brand indicated in the European Union and other territories for improvement of walking in adults with multiple sclerosis with walking disability. Company communications have described commercialization and supply responsibilities for neurological therapies across the United States and international territories, including product revenue from INBRIJA and AMPYRA and royalty or commercialization arrangements associated with FAMPYRA.

Acorda is headquartered in Pearl River, New York. Its public-company materials identify the company with the ACOR ticker and focus on the development, approval status, commercialization, and financial performance of therapies intended to address functional impairment in neurological disease.